

D²
M
S1

group consisting of breast cancer, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.

5. (Amended) The method of claim 1 wherein said cancer is breast cancer.
6. (Amended) The method of claim 1 wherein said cancer is metastatic breast carcinoma.

7. (Reiterated) The method of claim 1 wherein said antibody binds to an extracellular domain of ErbB2 receptor.

8. (Reiterated) The method of claim 7 wherein said antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.

9. (Reiterated) The method of claim 8 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.

12. (Reiterated) The method of claim 1 wherein the effective amount of said combination is lower than the sum of the effective amounts of said anti-ErbB2 antibody and said gemcitabine, when administered individually, as single agents.

D³
M
S1

13. (Amended) The method of claim 1 wherein efficacy is measured by determining time to disease progression or response rate.

34. (Reiterated) The method of claim 4 wherein said cancer is non-small cell lung cancer.

35. (Reiterated) The method of claim 4 wherein said cancer is pancreatic cancer.

36. (Reiterated) The method of claim 4 wherein said cancer is bladder cancer.

37. (Amended) A method for treating a cancer selected from the group consisting of breast cancer, non-small cell lung cancer, pancreatic cancer and

D4
AK
S1
A

bladder cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an anti-ErbB2 antibody and gemcitabine, in the absence of an anthracycline derivative, to a human patient in an amount effective to treat the cancer, wherein the antibody is not conjugated with the gemcitabine and the effective amount of the combination is lower than the sum of the effective amounts of the anti-ErbB2 antibody and the gemcitabine, when administered individually, as single agents.

Please add the following claim:

D5
AK
S1
A

38. (New) The method of claim 1 wherein the antibody is not conjugated with the gemcitabine.